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In industrialized countries, non-typhoidal Salmonella infections
are mainly associated with self-limited gastroenteritis; food ani-
mals and poultry serve as the reservoir and S. Typhimurium and
S. Enteritidis are prominent serovars causing foodborne illnesses.
Certain hosts (young infants, elderly, immunocompromised [e.g.,
AIDS patients]) occasionally develop severe invasive (septicemia,
meningitis, septic arthritis, etc.) as complications of gastroenteri-
tis. In the late 20th century, systematic bacteriologic culturing of
blood and ordinarily sterile body ﬂuids (cerebrospinal, synovial,
etc.) was undertaken in young children presenting fever or signs of
invasive bacterial disease (meningitis, etc.) in sub-Saharan Africa
sites. Surveillance was largely driven by the expectation (that con-
jugate vaccines to prevent invasive Haemophilus inﬂuenzae type b
(Hib), Streptococcus pneumoniae and Neisseria meningitidis would
be introduced in African countries. While these surveillance efforts
conﬁrmed the high incidence of invasive Hib and pneumococcal
disease in infants and toddlers, accompanied by high mortality
and sequelae, serendipitously, non-typhoidal Salmonella serovars
proved to be the third most common pathogen causing invasive
bacterial disease. High incidence rates (∼300/100,000 children)
and case fatality (∼20-30%) were recorded in East (Kenya), South-
ern (Mozambique) and West (Gambia) Africa. In these sites, as
well as in Rwanda, Mali and Malawi, two serovars, Typhimurium
(including monophasic ﬂagella variants) and Enteritidis comprised
∼75-95% of all cases. The majority of the burden of invasive
pediatric disease occurs in children<3 years of age with relative
sparing of very young infants (presumably due to maternal anti-
bodies). Clinically, two-thirds of pediatric cases do not manifest
gastroenteritis. The high case fatality (20-30%) and high incidence
make iNTS a major pediatric public health problem in sub-Saharan
Africa. Pediatric risk factors include severe malaria anemia, HIV
and severe malnutrition. Genomic studies revealed that most
invasive African S. Typhimurium strains are of an uncommon
MLST type and the organism is undergoing genomic degradation;
harboring pseudogenes also found in S. Typhi and S. Paratyphi
A. Clones of ST313 have spread throughout Africa. The severe
clinical disease, high mortality burden, restricted serovars, mul-
tiple antibiotic resistance and clustering of disease from 5–35
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One of the greatest challenges facing theworld today is the con-
trol of the Human Immunodeﬁciency Virus (HIV) epidemic. At the
end of 2012, an estimated 35.3million peoplewere livingwithHIV.
While intravenous drug use is the major route of transmission in
several countries, sexual transmission is the dominantmode of HIV
spread globally,with a concomitant epidemic in infants born toHIV
infected mothers. Although many regions and countries are show-
ing signs of declining or stabilizing epidemics, some countries and
populations continue to have unacceptably high HIV prevalence
and incidence rates.
Antiretroviral therapy (ART) has a dual role of both preventing
morbidity andmortality associatedwith advancingHIVdisease and
preventing HIV transmission. Since 2005, signiﬁcant advances in
scaling-up ART have been achieved globally and approximately 9.7
million people in low and middle-income countries were already
receiving ART by the end of 2012. Provision of ART to all those that
require it is essential but will not be sustainable if equal effort is
not invested in preventing new HIV infections.
Signiﬁcant advances in HIV prevention have been achieved in
the last decade. The scale up of prevention for mother-to-child
transmission for example has resulted in a drastic decline in new
HIV infections among children; which have decreased by 52%
between 2001 and 2012. Noteworthy achievements have also been
realised in scaling-up the implementation of circumcisions for
HIV prevention, with about 3.2 million adult African men having
received services for voluntary medical male circumcision by the
end of 2012.
Important new developments in preventing HIV have emerged
over the past 3 years that dramatically expand the available
prevention strategies for reducing sexually acquired HIV infec-
tions, especially for high-risk populations. Speciﬁcally, the use of
antiretroviral agents, as topical or oral prophylaxis, has been shown
to successfully reduce the risk of sexually transmitted. Despite
the numerous challenges in implementing these strategies, at high
adherence, these new interventions have created a newfound opti-
mism in HIV prevention. The challenge now is to mobilise the
political will and resources to translate these biomedical HIV pre-
vention technologies into public health impact to turn the tide of
the epidemic and perhaps end it.
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